Lantern Pharma Inc.
About Lantern Pharma Inc.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$17.1M
- Total assets
- $11.0M
- Market cap
- $45.8M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $18.0M
- Operating income
- -$18.0M
- Net income
- -$17.1M
- EPS (basic)
- $-1.57
- EPS (diluted)
- $-1.57
Balance sheet
- Total assets
- $11.0M
- Current assets
- $10.8M
- Total liabilities
- $4.5M
- Current liabilities
- $4.5M
- Shareholders’ equity
- $6.5M
Cash flow
- Operating cash flow
- -$15.7M
- Investing cash flow
- $11.1M
- Financing cash flow
- $1.5M
- Net cash flow
- -$3.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $45.8M
- EPS (diluted)
- $-1.57
- Shares outstanding
- 12.2M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 11, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $17.1M.
- Trading 30% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Lantern Pharma Inc..
Write a review
News about Lantern Pharma Inc.
News & sentiment via Polygon.io
